TP53 is a well-known tumor suppressor and is frequently mutated or deleted in CLL patients [56], while FOXP1 was reported to have an oncogenic role in B cell lymphoma and associated with poor clinical outcome [57, 58]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.